Socioeconomic impact of fibrositis: A study of 81 patients with primary fibrositis

Cathey, M A; Wolfe, Frederick; Kleinheksel, Sue M.; Hawley, Donna J.

doi:10.1016/0002-9343(86)90882-x

Cited by 71 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fibromyalgia can cause a high level of functional disability and have a significant negative impact on quality of life (QOL). The severity of self‐assessed disability in FM is similar to that of rheumatoid arthritis and osteoarthritis 7–10 . Pain, fatigue and weakness are most often reported to affect working capacity 11 …”

Section: Introductionmentioning

confidence: 85%

Quality of life in young fibromyalgia patients and effect of depression

Gür

Çevik

Nas

et al. 2006

APLAR Journal of Rheumatology

View full text Add to dashboard Cite

Aim: The purpose of this study was to compare the depression and quality of life (QOL) scores of fibromyalgia (FM) patients and control subjects. We also aimed to detect relationships between different QOL scales, depression and clinical symptoms. Method: Ninety‐eight fibromyalgia patients and 48 healthy volunteers were included in the study. Depression was evaluated by a psychiatrist according to the Hamilton Depression Rating Scale and Diagnostic and Statistical Manual for Mental Disorders Edition 4 (DSM‐IV) criteria. QOL of the FM patients was assessed according to the Nottingham Health Profile (NHP), Health Assessment Questionnaire (HAQ), and Fibromyalgia Impact Questionnaire (FIQ). Results: We found significantly higher scores of depression, NHP, FIQ and HAQ in FM patients compared with controls (P < 0.000). Pain, tender point count (TPC), pain intensity, skinfold tenderness, FIQ, HAQ, and NHP scores were higher in patients with depression than in those without depression. Depression scores correlated with FIQ (r = 0.39, P < 0.01), HAQ (r = 0.35, P < 0.01), NHP (r = 0.55, P < 0.01) scores, TPC (r = 0.34, P < 0.01) and duration of disease (r = 0.21, P < 0.05). Fibromyalgia Impact Questionnaire scores correlated with HAQ scores (r = 0.45, P < 0.01), NHP scores (r = 0.49, P < 0.01) and TPC (r = 0.21, P < 0.05). HAQ scores correlated with NHP scores (r = 0.40, P < 0.01) and TPC (r = 0.29, P < 0.05). Nottingham Health Profile scores correlated with TPC (r = 0.43, P < 0.01) and duration of disease (r = 0.22, P < 0.05). Conclusion: We found higher scores of TPC, pain intensity, skinfold tenderness, NHP, FIQ, and HAQ in depressive FM patients as compared with non‐depressive FM patients. Our study indicates that there is an important relationship between pain, depression and QOL scales in young FM patients. Therefore; these patients should be managed using a multidisciplinary approach including psychiatric support.

show abstract

Section: Introductionmentioning

confidence: 85%

Quality of life in young fibromyalgia patients and effect of depression

Gür

Çevik

Nas

et al. 2006

APLAR Journal of Rheumatology

View full text Add to dashboard Cite

show abstract

“…Extensive imaging and laboratory testing of these patients, often involving hundreds and even thousands of dollars, is frequently conducted to identify a possible inflammatory rheumatic disease, or other source of chronic pain, including malignancy (1)(2)(3)(4)(5). While self-report questionnaires clearly cannot replace all such maneuvers, a clue pointing to nonin- flammatory diffuse musculoskeletal pain with high probability in 50% of patients and with virtual certainty in 25% of patients could prove quite valuable.…”

Section: Discussionmentioning

confidence: 99%

A clue from a self‐report questionnaire to distinguish rheumatoid arthritis from noninflammatory diffuse musculoskeletal pain

Callahan

Pincus

1990

Arthritis & Rheumatism

View full text Add to dashboard Cite

A clue to distinguishing rheumatoid arthritis (RA) from noninflammatory diffuse musculoskeletal pain is described on the basis of 2 self-report questionnaire scales, one to assess difficulty in activities of daily living (D-ADL) and a pain visual analog scale (P-VAS). Patients with RA have significantly higher scores on the D-ADL scale compared with the P-VAS scale, while patients with noninflammatory diffuse musculoskeletal pain show the reciprocal pattern. Therefore, the ratio of the P-VAS:D-ADL scores differed significantly in the 2 groups. Ratios of <3 were seen in 67% of RA patients versus 28% of patients with noninflammatory diffuse musculoskeletal pain, while ratios >5 were seen in 27% of patients with noninflammatory diffuse musculoskeletal pain, but not in any patients with RA. This simple ratio is clearly not a diagnostic test, but provides an initial approach to diagnosis in rheumatic diseases using a self-report questionnaire.Rheumatoid arthritis (RA) and fibromyalgia are common problems seen in clinical practice (1-4). While these 2 entities in their classic forms are easily distinguished by experienced specialists, the distinc-

show abstract

“…Although fibromyalgia can strike at an early age, the mean age of onset in women has been reported as 44-53 years [1][2][3], similar to the mean age for menopause, 51 years [4]. Fibromyalgia affects 3.4% of women and 0.5% of men [5] or 2-4% of the population [6].…”

Section: Introductionmentioning

confidence: 99%

Treatment of pain in fibromyalgia patients with testosterone gel: Pharmacokinetics and clinical response

White

Brown

Gyurik

et al. 2015

International Immunopharmacology

View full text Add to dashboard Cite

To test our hypothesis that testosterone deficiency plays an important role in chronic pain, a Phase I/II pilot study was initiated with 12 fibromyalgia patients to verify that a daily dose for 28days with transdermal testosterone gel would 1) significantly and safely increase mean serum testosterone concentrations from low baseline levels to mid/high-normal levels, and 2) effectively treat the pain and fatigue symptoms of fibromyalgia. Pharmacokinetic data confirmed that serum free testosterone concentrations were raised significantly above baseline levels, by assessment of maximum hormone concentration (Cmax) and area under the curve (AUC) parameters: free testosterone Cmax was significantly raised from a mean of 2.64pg/mL to 3.91pg/mL (p<0.05), and 24hour free testosterone AUC was significantly raised from a mean of 35.0pg-hr/mL to 53.89pg-hr/mL. Assessment of the typical symptoms of fibromyalgia by patient questionnaire and tender point exam demonstrated significant change in: decreased muscle pain, stiffness, and fatigue, and increased libido during study treatment. These results are consistent with the hypothesized ability of testosterone to relieve the symptoms of fibromyalgia. Symptoms not tightly related to fibromyalgia were not improved.

show abstract

Socioeconomic impact of fibrositis: A study of 81 patients with primary fibrositis

Cited by 71 publications

References 9 publications

Quality of life in young fibromyalgia patients and effect of depression

Quality of life in young fibromyalgia patients and effect of depression

A clue from a self‐report questionnaire to distinguish rheumatoid arthritis from noninflammatory diffuse musculoskeletal pain

Treatment of pain in fibromyalgia patients with testosterone gel: Pharmacokinetics and clinical response

Contact Info

Product

Resources

About